{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:18:11Z","timestamp":1754558291794,"version":"3.41.2"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Glucose metabolism alterations in cystic fibrosis range from the classic cystic fibrosis-related diabetes (CFRD) to forms of glucose intolerance and prediabetes. The aim of the present work is to review the most up-to-date novelties in terms of CFRD diagnosis and therapy. This review is timely and relevant because it allows an update for the early and correct classification of glucose abnormalities in cystic fibrosis and because it favours an appropriate therapeutic approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Confirm that Oral Glucose Tolerance Test is still the diagnostic gold standard despite the advent of continuous glucose monitoring (CGM) systems; this latter is spreading very rapidly, however, to date, there is still no strong evidence to hypothesize the use of CGM for diagnostic purposes. CGM has indeed proven to be very useful in managing and guiding CFRD therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Tailored and personalized insulin therapy is still the recommended therapy for children and adolescents with CFRD, although nutritional intervention and oral hypoglycaemic treatment are equally important and efficacious. Finally CFTR modulators have allowed the increase of the life expectancy of cystic fibrosis patients and have proven effective not only in improving the pulmonary function and the nutritional status but also the glucose control.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001259","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T04:00:51Z","timestamp":1684728051000},"page":"481-485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Diabetes and prediabetes in children with cystic fibrosis"],"prefix":"10.1097","volume":"35","author":[{"given":"Riccardo","family":"Schiaffini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Pampanini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1242\/jcs.1993.Supplement_17.33","article-title":"Dysfunction of CFTR bearing the delta F508 mutation","volume":"17","author":"Welsh","year":"1993","journal-title":"Cell Sci Suppl"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/adc.65.1.152","article-title":"Cystic fibrosis","volume":"65","author":"David","year":"1990","journal-title":"Arch Dis Child"},{"key":"R3-20250730","first-page":"576","article-title":"Carbohydrate metabolism impairment in children and adolescents with cystic fibrosis","volume":"69","author":"Garc\u00eda","year":"2022","journal-title":"Endocrinol Diabetes Nutr"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/MOP.0000000000000251","article-title":"Advances in the detection and management of cystic fibrosis-related diabetes","volume":"27","author":"Hameed","year":"2015","journal-title":"Curr Opin Pediatr"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc08-1925","article-title":"Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study","volume":"32","author":"O\u2019Riordan","year":"2009","journal-title":"Diabetes Care"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2022.07.013","article-title":"Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis","volume":"22","author":"Kumar","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A1c accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabetes Care"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"673539","DOI":"10.3389\/fendo.2021.673539","article-title":"Diabetes and prediabetes in children with cystic fibrosis: a systematic review of the literature and recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)","volume":"29","author":"Mozzillo","year":"2021","journal-title":"Front Endocrinol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5114\/aoms.2016.59268","article-title":"Predictors of deterioration of lung function in Polish children with cystic fibrosis","volume":"2","author":"Olszowiec-Chlebna","year":"2016","journal-title":"Arch Med Sci"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J Cyst Fibros"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/jpem-2019-0484","article-title":"Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment","volume":"33","author":"Alves","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"(Suppl 2)","key":"R15-20250730","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic fibrosis related diabetes: nutrition and growth considerations","volume":"18","author":"Kaminski","year":"2019","journal-title":"J Cyst Fibros"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jcjd.2023.02.002","article-title":"Canadian cystic fibrosis-related diabetes clinical practice survey: analysis of current practices and gaps in clinical care","volume":"47","author":"Potter","year":"2023","journal-title":"Can J Diabetes"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cysticfibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R18-20250730","first-page":"CD004730","article-title":"Drug treatments for managing cystic fibrosis-related diabetes","volume":"10","author":"Onady","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of Sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"(Suppl 2)","key":"R20-20250730","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clnu.2014.08.016","article-title":"Carbohydrate intake and insulin requirement in children, adolescents and young adults with cystic fibrosis-related diabetes: a multicenter comparison to type 1 diabetes","volume":"34","author":"Scheuing","year":"2015","journal-title":"Clin Nutr"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","article-title":"Use of the insulin pump in treat cystic fibrosis related diabetes","volume":"8","author":"Hardin","year":"2009","journal-title":"J Cyst Fibros"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/dia.2021.0354","article-title":"The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","volume":"24","author":"Scully","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17476348.2023.2179989","article-title":"Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor\/tezacaftor\/ivacaftor combination therapy","volume":"17","author":"Jordan","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"R25-20250730","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis related diabetes following initiation of Elexacaftor\/Tezacaftor\/Ivacaftor","author":"Park","year":"2023","journal-title":"Horm Res Paediatr"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:02:47Z","timestamp":1753898567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001259","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"type":"print","value":"1040-8703"},{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}